

**Joshua R. Steiner, M.D.**

Bala Cynwyd, Pennsylvania • jrsteiner@gmail.com • (610) 724-3294

*Curriculum Vitae*, August 2023

**Pharmaceutical Industry Experience**

2018-  
present

**Jazz Pharmaceuticals**

Vice President, Neuropsychiatry

Formerly GW Pharmaceuticals (2019-2021), acquired by Jazz

Executive Director, Clinical Development (2018-2019)

- Lead cross-functional development team for novel neurotherapeutics
- Led department of 15+ team members spanning Early Clinical Development, Clinical Pharmacology, Portfolio & Translational Strategy, Search & Evaluation
- Architect and execute Jazz CNS R&D growth strategy
- Provide strategic leadership for GW R&D, culminating in Jazz acquisition
- Spearhead development of new R&D capabilities
- Enterprise-wide framework for Real World Evidence
- Digital Health Working Group
- Interdisciplinary research strategy in Translational Neuroscience

2013-2018

**Teva Pharmaceuticals**

Therapeutic Area Head, Multiple Sclerosis and Headache

Senior Director, Global Clinical Development (2016-2018)

Director, Global Clinical Development (2013-2016)

- Lead and influence via cross-functional matrices and direct reports
- Execute clinical trials to ensure medical and scientific integrity
- Provide strategy and due diligence for business development activities
- Disseminate clinical data via publications and presentations
- Key achievements:
- Copaxone 40mg sNDA approval
- Phase 2, 3, 3b trials in Multiple Sclerosis
- Phase 3, 3b trials in Headache and Migraine
- Governance of portfolio of 8 CNS projects

2011-2013 **CRI Lifetree**

Medical Director, Neurology

- Principal Investigator or Sub-Investigator on 50+ Phase 1-4 clinical trials in Alzheimer's disease, Multiple Sclerosis, Parkinson's disease, Schizophrenia, Depression, Bipolar, Pain, Smoking Cessation, Diabetes, hypertension, Infectious Disease, and other therapeutic indications
- Reported directly to the CEO of this growth-phase clinical trials company acquired by PRA Health Sciences

### **Entrepreneurial/Board Experience**

2012- Click Therapeutics, New York, New York

- Co-founded digital therapeutics company to develop, validate, and commercialize software as prescription medical treatments; consultant and board observer

2020- Board Director, Kohelet Yeshiva, Merion Station, Pennsylvania

2006-2014 Founder, ProGeivity Neuroscience, acquired by Click Therapeutics

2011-2013 Clinical Advisory Board, Lexercise, Raleigh, North Carolina

### **Academic Experience and Postdoctoral Training:**

2008-2013 **Albert Einstein College of Medicine**, Bronx, New York

Assistant Professor of Neurology (2008-2011)

Clinical Assistant Professor of Neurology (2011-2013)

2006-2008 **Columbia University Medical Center**, New York, New York

Clinical Research Fellow (Cognitive Neuropsychiatry)

Neurological Institute and Psychiatric Institute

2003-2006 **Yale University School of Medicine**, New Haven, Connecticut

Resident in Neurology

## Education

- 1998-2002 **State University of New York-Downstate Medical Center, Brooklyn**  
M.D. with commendation in investigative scholarship
- 1996-1998 **Columbia University**, New York, New York  
Postbaccalaureate Premedical Program
- 1992-1996 **Harvard University**, Cambridge, Massachusetts A.B., *Magna cum laude*

## Board Certification, Medical Licensure, Clinical Appointments

- Board Certified in Neurology, American Board of Psychiatry and Neurology  
Board Certified in Behavioral Neurology and Neuropsychiatry, UCNS (inactive)  
Licensed in New York (241255), New Jersey (25MA08980500), Pennsylvania (MD443645)
- 2012-2013 Neurohospitalist, Virtua, Marlton, New Jersey
- 2008-2011 Attending Neurologist, Montefiore Medical Center, Bronx, New York,
- 2006-2011 Neurohospitalist, White Plains Hospital Center, White Plains, New York,
- 2006-2008 Assistant Attending Neurologist, New York-Presbyterian, New York, New York,
- 2002-2003 Intern in Medicine, Maimonides Medical Center, Brooklyn, New York,

## Research Investigator Experience

- 2013 Principal Investigator, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of XXXXX in Subjects with Mild to Moderate Alzheimer's Disease. Sponsor: TauRx
- 2012-2013 Principal Investigator, A Phase 1 Randomized Study of XXXXX in Subjects with Relapsing-Remitting Multiple Sclerosis. Sponsor: Medimmune
- 2012-2013 Principal Investigator, A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of XXXXX in Patients with Parkinson's Disease. Sponsor: AstraZeneca
- 2012-2013 Principal Investigator, A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXXX in Subjects with Prodromal or Mild Alzheimer's

Disease. Sponsor: Biogen

- 2012-2013 Principal Investigator, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Two Year Study to Evaluate the Effect of Subcutaneous XXXXX on Cognition and Function in Prodromal Alzheimer's Disease. Sponsor: Roche
- 2012-2013 Principal Investigator, A Phase 2, randomized, double-dummy, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of XXXXX for the treatment of symptoms of agitation in patients with Alzheimer's disease. Sponsor: Avanir
- 2011-2012 Principal Investigator, An Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetic Profile of XXXXX in Patients Diagnosed with Parkinson's Disease. Sponsor: Hisamitsu
- 2011-2013 Sub-Investigator, 50+ Phase I-IV clinical trials in Schizophrenia, Depression, Bipolar, Pain, Smoking Cessation, Binge Eating Disorder, Diabetes, Hypertension, Infectious Disease
- 2009-2011 Principal Investigator, Brain Aging Knowledge, Attitudes, and Beliefs in a Naturally Occurring Retirement Community, Center for Healthy Brain Aging
- 2009-2011 Principal Investigator, Focus Groups for Community Brain Health Research Design, Center for Healthy Brain Aging
- 2008-2011 Investigator, Einstein Aging Study, Albert Einstein College of Medicine
- 2009-2011 Co-investigator, Platform for Mental Fitness Efficacy Studies, Technology for Aging Gracefully Laboratory, University of Toronto
- 2008-2011 Co-investigator, Lifelogging Multimedia Technology Review for Memory-Impaired Elders, TAGlab, University of Toronto
- 2006-2009 Co-investigator, Training Control Processes in Cognitively-Healthy Older Adults, Division of Cognitive Neuroscience, Columbia University Medical Center
- 2008-2009 Principal Investigator, Safety and efficacy of positron emission tomography imaging with XXXXX. Sponsor: Bayer HealthCare

- 2006-2008 Sub-investigator, 13 clinical trials in Alzheimer's disease and Mild Cognitive Impairment, Columbia University Medical Center
- 2006-2008 Research neurologist, Washington Heights-Inwood Community Aging Project, Columbia University Medical Center, New York, NY
- 2006-2008 Research neurologist, Alzheimer's Disease Research Center, Columbia University Medical Center
- 2001 Research assistant, Laboratory of Patrick Hof, M.D., Department of Neuroscience, Mount Sinai Medical Center, New York, NY
- 1999 Research assistant, Laboratory of Robert Muller, Ph.D., Department of Physiology, SUNY-Downstate Medical Center, Brooklyn, NY
- 1998-1999 Research assistant, Laboratory of Ilana Gozes, Ph.D., Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv, Israel

## Bibliography

### Original Articles

Nicholas J, Lublin F, Klineova S, Berwaerts J, Chinnapongse R, Checketts D, Javaid S, **Steinerman JR**. Nabiximols efficacy in people with MS with spasticity: treatment effects on spasticity Numeric Rating Scale, muscle spasm frequency, and spastic muscle tone in 2 randomized clinical trials. *Multiple Sclerosis and Related Disorders* 2023; 75:10475. (PMID 37209500)

Cameron M, Bethoux F, Field-Fote E, Lenderking WR, Zaiser E, Cutts KN, Wagner JM, Berwaerts J, **Steinerman JR**. Development of an Integrated Conceptual Model of Multiple Sclerosis Spasticity. *Disability and Rehabilitation* 2023 (PMID: 37480330)

Salter A, Cutter G, Marrie RA, Nichol K, **Steinerman JR**, Smith KMJ, Fox RJ. Sources of Cannabis Information and Medical Guidance for Neurological Use: NARCOMS Survey of People Living with Multiple Sclerosis. *Neurology Clinical Practice* 2022; 12(2):102-112. (PMID: 35733947)

Salter A, Fox RJ, Cutter G, Marrie RA, Nichol KE, **Steinerman JR**, Smith KMJ. A Survey of Cannabis Use in a Large US-Based Cohort of People Living With Multiple Sclerosis. *International Journal of MS Care* 2021; 23(6):245-252. (PMID: 35035295)

Comi G, Dadon Y, Sasson N, **Steinerman JR**, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick

S, Halevy N, Filippi M. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. *Multiple Sclerosis* 2021 (PMID: 34378456)

Videnovic A, Amara A, Comella C, Schweitzer P, Emsellem H, Liu K, Sterkel AL, Gottwald MD, **Steinerman JR**, Jochelson P, Zomorodi K, Hauser RA. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. *Movement Disorders* 2021; 36:2408-2412. (PMID: 34191352)

Giovannoni G, Knappertz V, **Steinerman JR**, Tansy AP, Li T, Krieger S, Uccelli A, Uitdehaag BMJ, Montalban X, Hartung HP, Sormani MP, Cree BAC, Lublin F, Barkhof F. A randomized, placebo-controlled phase 2 trial of laquinimod in primary progressive multiple sclerosis. *Neurology* 2020. (PMID: 32651286)

Bovis F, Carmisciano L, Signori A, Pardini M, **Steinerman JR**, Li T, Tansy AP, Sormani MP. Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data. *BMC Med* 2019;17(1):113. (PMID: 31208412)

Bovis F, De Stefano N, **Steinerman JR**, Knappertz V, Sormani MP. Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS. *Multiple Sclerosis* 2019; 25(2):217-223. (PMID: 29154721)

Bovis F, Signori A, Carmisciano L, Maietta I, **Steinerman JR**, Li T, Tansy AP, Sormani MP. Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas. *Annals of Neurology* 2018; 84(4): 621-625. (PMID: 30179270)

Koch MW, Cutter GR, Giovannoni G, Uitdehaag BMJ, Wolinsky JS, Davis MD, **Steinerman JR**, Knappertz V. Comparative utility of disability progression measures in PPMS. Analysis of the PROMiSe data set. *Neurology Neuroimmunology Neuroinflammation* 2017;4(4):e358. (PMID: 28680915)

Davis MD, Ashtamker N, **Steinerman JR**, Knappertz V. Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. *Neurology Neuroimmunology Neuroinflammation* 2017; 4(2): e327.

Iacoviello BM, **Steinerman JR**, Klein DB, Silver TL, Berger AG, Luo SX, Schork NJ. Clickotine, A Personalized Smartphone App for Smoking Cessation: Initial Evaluation *JMIR Mhealth Uhealth* 2017; 5(4):e56.

Zivadinov R, Dwyer MG, Ramasamy DP, Davis MD, **Steinerman JR**, Khan O. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Relmitting Multiple Sclerosis. *Journal of Neuroimaging* 2015; 25(6):989-95.

Wolinsky JS, Borresen TE, Dietrich DW, Wynn DR, Sidi Y, **Steinerman JR**, Knappertz V, Kolodny S, on behalf of the GLACIER Study Group. GLACIER: an open-label, randomized,

multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg/mL three-times weekly versus 20 mg/mL daily in patients with relapsing-remitting multiple sclerosis. *Multiple Sclerosis & Related Disorders* 2015;4(4):370–376.

Zivadinov R, Dwyer M, Barkay H, **Steinerman JR**, Knappertz V, Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1- hypointense "black holes": a post hoc magnetic resonance imaging analysis. *Journal of Neurology* 2015; 262(3):648-53.

White R, Lipton RB, Hall CH, **Steinerman JR**. Non-melanoma Skin Cancer is Associated with Reduced Alzheimer's Risk. *Neurology* 2013;80(21):1966-72.

**Steinerman JR**, Lipton RB, Rapkin BD, Quaranto BR, Schwartz CR. Factors associated with openness to research participation in an aging community: The importance of technophilia and social cohesion. *Gerontechnology* 2013, 11(4): 504-512.

Crete-Nishihata M, Baecker RM, Massimi M, Ptak D, Campigotto R, Kaufman L, Brickman AM, Turner G, **Steinerman JR**, Black SE. Reconstructing the past: personal memory technologies are not just personal and not just for memory. *Human-Computer Interaction* 2012, 27:92-123.

**Steinerman JR**. Minding the Aging Brain: Technology-Enabled Cognitive Training for Healthy Elders. *Current Neurology and Neuroscience Reports* 2010, 10(5):374-380.

Blumen HB, Gopher D, **Steinerman JR**, Stern Y. Training Cognitive Control in Older Adults with the Space Fortress Game: The Role of Training Instructions and Basic Motor Ability. *Frontiers in Aging Neuroscience* 2010, 2:145.

**Steinerman JR**, Sliwinski MJ, Hall CB, Lipton RB. Modeling Cognitive Trajectories Within Longitudinal Studies: A Focus on Elders. *Journal of the American Geriatrics Society* 2010, 58:S313-318.

**Steinerman JR**, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M, Blacker D, Hyman B, Stern Y. Distinct Pools of  $\beta$ -amyloid in Alzheimer Disease-Affected Brain: A Clinical-Pathological Study. *Archives of Neurology* 2008, 65(7): 906-912.

**Steinerman JR**, Honig LS. Laboratory Biomarkers in Alzheimer's Disease. *Current Neurology and Neuroscience Reports* 2007, 7:381-387.

## **Book Chapters**

**Steinerman JR**, Lipton RB. “Alzheimer’s Disease,” in S.K. Whitbourne and Sliwinski, M.J. (eds.) *The Wiley-Blackwell Handbook of Adulthood and Aging*, First edition (United Kingdom: Blackwell, 2012) 293-311.

**Steinerman JR**, Marder KS. “Lewy Body Dementias,” in L.P. Rowland and Pedley, T.A. (eds.) *Merritt’s Neurology 12<sup>th</sup> edition* (Philadelphia: Lippincott, 2010) 721-722.

**Steinerman JR**, Noe E, Stern Y. “Cognitive Aspects of Parkinson’s Disease and Other Neurodegenerative Movement Disorders,” in J.I. Sirven and Malamut, B.L. (eds.) *Clinical Neurology of the Older Adult* (Philadelphia: Lippincott, 2008) 376-392.

### **Grant Support**

2010-2011 Einstein-Montefiore Institute for Clinical and Translational Research Career Development Award, NIH grants KL2RR025749, UL1RR025750

2006-2011 NIH Clinical Research Loan Repayment Program

2009-2010 Brain Aging Knowledge, Attitudes, and Beliefs in an Urban Naturally-Occurring Retirement Community, Resnick Gerontology Center Pilot Grant

2006-2008 National Research Service Award NIH/NIMH training grant 5T32MH020004

### **Committee Memberships**

2010-2017 Data Safety Monitoring Board, “Exercise, Aging, and Cognition: Effects and Mechanisms” PI: Yaakov Stern, PhD

2010-2011 Technology Interest Area, International Society to Advance Alzheimer’s Research and Treatment (ISTAART), Alzheimer’s Association

2009-2010 Health Inequities Think Tank, Division of Community Collaboration and Implementation Science, Albert Einstein College of Medicine

### **Awards**

2010 Louis and Gertrude Feil Faculty Scholar in Neurology, Office of the Dean, Albert Einstein College of Medicine



- 2010 Men's Division Research Scholar, Albert Einstein College of Medicine
- 2009 Travel Fellowship Award, International Conference on Alzheimer's Disease, Vienna, Austria
- 2007 Travel Fellowship Award, American Neurological Association, 132<sup>nd</sup> Annual Meeting, Washington, D.C.
- 2006 Resident of the Year (Teaching Excellence), Department of Neurology, Yale School of Medicine
- 2002 Commendation in Investigative Scholarship, Downstate College of Medicine
- 2001 Medical Student Geriatric Scholar, American Federation for Aging Research
- 1996 *Magna Cum Laude*, Harvard College
- 1993-1995 John Harvard Scholarship for Academic Achievement
- 1992 Valedictorian, Lawrence High School, Cedarhurst, NY

### **Languages**

Proficient in Spanish, Hebrew, Yiddish